Todd L. Saretsky

Statistics

Publications

Citations

H-Index

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Hôpital Saint-André

Beatson West of Scotland Cancer Centre

Dana-Farber Cancer Institute

Todd L. Saretsky is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cancer immunotherapy, oncology, and euroqol five dimensions.

Publications per year

2016–2025

Publications

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · The Oncologist · 2023 · 23 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

Richard W. Joseph, Frank Xiaoqing Liu, Alicia C. Shillington et al. · Quality of Life Research · 2020 · 22 citations · Full text

Pharmacy, Immunology, Oncology +16

Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response

Kristen Johnson, Jacob Devine, Kai Fai Ho et al. · The Journal of Clinical Psychiatry · 2016 · 20 citations

Nursing, Psychiatry, Psychology +17

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro et al. · Blood Advances · 2021 · 20 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial

Thomas Powles, Toni K. Choueiri, Laurence Albigès et al. · The Lancet Oncology · 2025 · 10 citations

Medicine, Oncology, Pharmacotherapy +11

1–5 of 5